#Taiwan #Taipei #Foresee Pharmaceuticals #Primevera Therapeutics #MMP-12 Inhibitors

Foresee Pharmaceuticals Partners with Primevera Therapeutics

In an exciting development within the biopharmaceutical industry, Foresee Pharmaceuticals has officially signed a global licensing agreement with Primevera Therapeutics, LLC for its MMP-12 inhibitor programs, marking a significant milestone for the company. The announcement follows approval at Foresee's recent Extraordinary General Shareholders' Meeting, which took place in 2025.

This agreement entails exclusive global rights concerning Foresee's innovative MMP-12 inhibitors, which include FP-025, FP-020, and third-generation inhibitors currently in drug discovery. As part of the deal, Foresee USA, Foresee Pharmaceuticals’ wholly-owned US subsidiary, will receive an upfront payment of $10 million, along with future milestone payments that may reach up to $574.5 million. Furthermore, the agreement includes tiered single-digit royalties on sales and allows Foresee to maintain a 19% equity stake in Primevera.

“By partnering with Primevera, we are taking a strategic step toward streamlining our operations while boosting our financial positioning,” said Dr. Ben Chien, the Chairman and CEO of Foresee Pharmaceuticals. This partnership is set to have a material positive impact on Foresee's working capital and shareholder equity, reinforcing its commitment to sustainable and profitable growth.

The licensing deal comes at a crucial point in Foresee's growth trajectory, enabling the company to concentrate on its SIF (Stabilized Injectable Formulation) portfolio. With plans to build its revenue stream, Foresee aims to prioritize resources on CAMCEVI, their innovative 6-month long-acting injectable recently completing a successful Phase 3 study for treating central precocious puberty (CPP). A New Drug Application (NDA) submission for CAMCEVI is targeted for 2026, and its 3-month formulation, expected to launch in the fourth quarter of 2026, holds significant commercial potential.

Under the new agreement, Primevera will take over all costs associated with the MMP-12 inhibitors moving forward. Their development focus will include:

• - FP-020: Anticipated submission of an Investigational New Drug (IND) application for a Phase II clinical trial in asthma, expected within early 2026.
• - FP-025: Preparations for Phase II clinical trials in indications related to rare diseases.

Foresee's long history in the discovery and development of MMP-12 inhibitors has allowed the company to gain recognition as a leader within that space over the past ten years. This partnership with Primevera promises to further advance Foresee's mission while positioning it favorably on the path to profitability.

About Foresee Pharmaceuticals

Foresee Pharmaceuticals is a biopharmaceutical company based in Taiwan and the US, listed on the Taipei Exchange (TPEx 6576). It focuses its research and development on two main areas: its proprietary Stabilized Injectable Formulation (SIF) technology designed for long-acting injectables targeting specialty markets, and innovative new chemical entities (NCEs) aimed at addressing severe and rare diseases with significant unmet needs.

The company’s product pipeline includes both late-stage and early-stage programs that showcase a range of therapeutic potentials. Foresee's flagship product, CAMCEVI, used for treating advanced prostate cancer, has already received approval across multiple regions, including the U.S., Canada, EU, Taiwan, and the UK. In recent announcements, CAMCEVI ETM was approved by the U.S. FDA in August 2025, and further investigations into its 6-month formulation for CPP continue.

In addition to its ongoing developments, Foresee has several promising projects targeting various therapeutic areas. Aderamastat (FP-025), a selective oral MMP-12 inhibitor not only completed a Phase 2 proof-of-concept study in asthma but also shows promise in treating immune-fibrotic diseases. Meanwhile, Linvemastat (FP-020) has also successfully reached important development milestones.

Overall, as Foresee embarks on this new chapter, the future appears bright for the company, with various strategic moves aimed at capital efficiency and bolstering its competitive position in the market.